Home > Insider Trading > Filing (0000898432-20-000015)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1325618	Iradimed Corp	IRMD	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1254747	Brent Johnson	C/O Iradimed Corporation 1025 Willa Springs Dr. Winter Springs FL 32708	Exec. Vp. Sales And Mktg	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-12-31	617	$0.00	3,183	No	4	M	Direct
Common Stock	Disposition	2019-12-31	243	$23.38	2,940	No	4	F	Direct
Common Stock	Acquisiton	2019-12-31	6,000	$0.93	8,940	No	4	A	Direct
Common Stock	Disposition	2019-12-31	6,000	$23.79	2,940	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2019-12-31	617	$0.00	617	$0.00
Common Stock	Stock Option(Right to Buy)	Disposition	2019-12-31	6,000	$0.00	6,000	$0.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct
126,468		2022-11-01	No	4	M	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
On January 4, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on January 4, 2017. The scheduled January 4, 2020 vesting was accelerated by the registrant, and the restricted stock units became vested as of December 31, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.
This transaction was executed in multiple trades at prices ranging from $23.65 to $23.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.